第7回日経・FT感染症会議 - NIKKEI FT Communicable Diseases Conference

開催日 2019年8月31日（土）・9月1日（日）参加料無料 事前登録抽選制 dates August 31 (Sat.) - September 1 (Sun.) 2019 FREE Admission Pre-registration/Selection
Statement - ステートメント
The 7th Nikkei FT
Communicable Diseases Conference
‘Yokohama Communicable Diseases Statement 2020’
第7回日経・FT感染症会議
「横浜感染症ステートメント2020」

Program - プログラム

DAY1November 6( Fri.) 11月6日(金)

* Please note that program details may be subject to change.
* Simultaneous interpretation is available at this conference

*プログラム内容は変更になる場合がございます。
*この会議では同時通訳が利用できます。

9:30-9:40

Opening Remarks開会挨拶

Mr. Yoshihiro HIRATA

Senior Managing Director
Media Business
Nikkei Inc.
9:40-10:00

Keynote Speech - Prof. Baron peter piot KCMG MD PhD基調講演　ピーター・ピオット博士（英ロンドン大学衛生・熱帯医学大学院学長）

Prof. Baron PETER PIOT KCMG MD PhD

Director and Handa Professor of Global Health
London School of Hygiene & Tropical Medicine
10:00-10:15

Agenda1- Introduction: Overview of COVID-19 Measures議題1　尾身茂議長から：新型コロナ対策の Overview

Dr. Shigeru OMI, MD, PhD

President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
World Health Organization (WHO), Regional Office for Western Pacific
10:15-12:20

Agenda2- Inspection of COVID-19 measures and Identification of Issues議題2　COVID-19への対応検証と課題抽出

Moderator

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Click here for a list of discussers

  • Hajime INOUE, MD, MPH, DrPH　

    Deputy Director General
    Office for Novel Coronavirus Disease Control, Cabinet Secretariat

  • Norio OHMAGARI, M.D., M.Sc., Ph.D.

    Disease Control and Prevention Center / Director
    National Center for Global Health and Medicine Hospital

  • Dr. Nobuhiko OKABE, MD, Ph.D.

    Director General,
    Kawasaki City Institute for Public Health

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Prof. Osamu KUNII, MD, MPH, PhD,　

    Head, Strategy, Investment and Impact Division (SIID)
    The Global Fund to Fight AIDS, Tuberculosis and Malaria

  • Tomoya SAITO, MD, MPH, PhD

    Director, Dept of Health Crisis Management
    National Institute of Public Health

  • Dr. Junko SATO, PhD

    Office Director, Office of International Program,
    Pharmaceuticals and Medical Devices Agency

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE)，World Health Organization

  • Dr. Masaya SUGIYAMA, PhD

    Institute/ Vice Project Leader
    National Center for Global Health and Medicine

  • Dr. Motoi SUZUKI, MD PhD

    Director
    Infectious Disease Surveillance Center
    National Institute of Infectious Diseases

  • Dr. SUZUKI Yasuhiro

    Advisor to the Minister
    Ministry of Health, Labor & Welfare

  • Prof. Hiromitsu TAZAWA

    Professor of Clinical Bioresource Center
    Kyoto University’s Hospital　

  • Dr. Kazuhiro TATEDA, MD, PhD

    Department of Microbiology and Infectious Diseases/professor
    Toho University School of Medicine

  • Mikihito TANAKA, Ph.D.

    Associate Professor
    Graduate School of Political Science,
    Waseda University

  • Mr. Hideki TARUMI

    Vice-Minister
    Ministry of Health, Labour and Welfare

  • Prof. Jiro FUJITA, MD, PhD, FCCP

    Professor,
    University of the Ryukyus Hospital

  • Prof. Kaori MUTO

    Professor / Department of Public Policy, Human Genome Center
    The Institute of Medical Science, The University of Tokyo

  • Mr. Peter SANDS

    Executive Director
    The Global Fund to Fight AIDS, Tuberculosis and Malaria
12:30-13:30

Lunch Session- BD Japan　The role of testing in communicable diseases～Learning from COVID-19ランチセッション　日本ベクトン・ディッキンソン　感染症における検査のあり方～COVID-19から学ぶ～

Moderator

Mr. Ryoji NORITAKE

CEO and Board Member,
Health and Global Policy Institute (HGPI)

Click here for a list of discussers

  • Prof. Mr. Ataru IGARASHI, PhD

    Associate Professor Unit of Public Health and Preventive Medicine, School of Medicine,
    Yokohama City University

  • Dr. Junzo SHIMIZU, MD, PhD

    Director Department of Surgery,
    Toyonaka Municipal Hospital

  • Mr. Satoshi TAKAGI

    Business Director, Integrated Diagnostic Solutions
    Nippon Becton Dickinson Company, Ltd.

  • Dr. Kazuhiro TATEDA, MD, PhD

    Department of Microbiology and Infectious Diseases/professor
    Toho University School of Medicine
13:40-14:30 Breakout Session A-1 分科会　A-1 Breakout Session B-1 分科会　B-1 Breakout Session C-1 分科会　C-1

A-1 SHIONOGI／ DAIICHI SANKYO CO., LTD.

Challenges and Efforts to Address the Threat of Infectious Diseases - Learning from the Cases of AMR and COVID-19感染症の脅威に対する課題と取り組み　～AMRとCOVID-19の事例から学ぶ～

Moderator

Dr. Norihito UEDA, MD, PhD

Senior Medical Director, Biologics Division
DAIICHI SANKYO CO., LTD.

Dr. Yoshinori YAMANO, Ph.D.

Chief Scientific Officer for Infectious Diseases,
Pharmaceutical Research Division,
SHIONOGI & CO., LTD.

Click here for a list of discussers

  • Hajime INOUE, MD, MPH, DrPH　

    Deputy Director General
    Office for Novel Coronavirus Disease Control, Cabinet Secretariat

  • Mr. Masayuki IMAGAWA, M.B.A., M.Sc., R.Ph.

    Head, Japan Vaccine Business Unit,
    Takeda Pharmaceutical Co., Ltd
    Chief Executive,
    Japan Association of Vaccine Industries

  • Norio OHMAGARI, M.D., M.Sc., Ph.D.

    Disease Control and Prevention Center / Director
    National Center for Global Health and Medicine Hospital

  • Dr. Nobuhiko OKABE, MD, Ph.D.

    Director General,
    Kawasaki City Institute for Public Health

  • Mr. Tatsuro KUZUKI

    Scientific Liaison
    DNDi Japan

  • Dr. Kazuhiro TATEDA, MD, PhD

    Department of Microbiology and Infectious Diseases/professor
    Toho University School of Medicine

  • Yasunori TAWARAGI, PhD

    Director, International Affairs
    Japan Pharmaceutical Manufacturers Association

  • Dr. Yohei DOI, MD, PhD

    Departments of Microbiology and Infectious Diseases
    Fujita Health University
    Division of Infectious Diseases
    University of Pittsburgh

  • Mr. Ryoji NORITAKE

    CEO and Board Member,
    Health and Global Policy Institute (HGPI)

  • Mr. Mitsushiro HIRAI

    Project Lead, Japan
    Bill & Melinda Gates Foundation

  • Shoji MIYAGAWA, DVM.MS

    Director, Division of Basic Medical Research,
    Department of Basic Medical Research,
    the Japan Agency for Medical Research and Development

B-1 H.U. Group Holdings, Inc.

Optimal COVID-19 test selection based on characteristic of testing method検査手法の特性を踏まえた新型コロナウイルス感染症の最適な検査選択について

Moderator

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Click here for a list of discussers

  • Mr. Goki ISHIKAWA

    Executive Officer (IVD)
    H.U. Group Holdings, Inc.
    President and CEO
    Fujirebio Holdings, Inc.

  • Kazuya OMI, Ph.D.

    Executive Officers (Research and Development)　
    H.U. Group Holdings, Inc.,
    President
    H.U. Group Research Institute G.K.,

  • Dr. Kazuhiro TATEDA, MD, PhD

    Department of Microbiology and Infectious Diseases/professor
    Toho University School of Medicine

  • Dr. Hiroyuki NODA, MD, PhD

    Office for Novel Coronavirus Disease Control,
    Office for Pandemic Influenza and New Infectious Diseases
    & Coordination Office of Measures on Emerging Infectious Disease / Councilor
    Cabinet Secretariat

  • Prof. Dr. Hayato MIYACHI, MD, PhD

    Professor Department of Laboratory Medicine
    Tokai University School of Medicine

C-1 FUMAKILLA LIMITED

Inactivation of novel corona virus by low-alcohol products - Possibility of contributing to countermeasures in daily life低アルコール製剤による新型コロナウイルス不活化効果について～日常生活における対策への貢献の可能性

Moderator

Mr. Yasuhide YAMADA

Former Director-General of Coordination Office of Measures on Emerging Infectious Diseases, Cabinet Secretariat, Government of Japan
Executive Officer, SHIMIZU CORPORATION

Click here for a list of discussers

  • Mr. Takashi AKASAKA

    RESERCH & DEVELOPMENT DIVISION SENIOR RESEARCHER
    RESERCH & DEVELOPMENT DEPARTMENT
    FUMAKILLA LIMITED

  • Prof. Dr. Takemasa SAKAGUCHI, MD, PhD

    Graduate School of Biomedical and Health Sciences
    Hiroshima University

  • Prof. Go TANAKA, MD, MPH, PhD

    Executive Technical Advisor at Human Development Department,
    Japan International Cooperation Agency

  • Director. Dr. Hideaki HANAKI, Ph, PhD

    Director, Infection Control Research Center, Kitasato University
14:40-15:30 Breakout Session A-2分科会　A-2 Breakout Session B-2分科会　B-2 Breakout Session C-2分科会　C-2

A-2 SHIONOGI／ DAIICHI SANKYO CO., LTD.

Challenges and Efforts to Address the Threat of Infectious Diseases - Learning from the Cases of AMR and COVID-19感染症の脅威に対する課題と取り組み　～AMRとCOVID-19の事例から学ぶ～

Moderator

Dr. Norihito UEDA, MD, PhD

Senior Medical Director, Biologics Division
DAIICHI SANKYO CO., LTD.

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Dr. Yoshinori YAMANO, Ph.D.

Chief Scientific Officer for Infectious Diseases,
Pharmaceutical Research Division,
SHIONOGI & CO., LTD.

Click here for a list of discussers

  • Hajime INOUE, MD, MPH, DrPH　

    Deputy Director General
    Office for Novel Coronavirus Disease Control, Cabinet Secretariat

  • Mr. Masayuki IMAGAWA, M.B.A., M.Sc., R.Ph.

    Head, Japan Vaccine Business Unit,
    Takeda Pharmaceutical Co., Ltd
    Chief Executive,
    Japan Association of Vaccine Industries

  • Norio OHMAGARI, M.D., M.Sc., Ph.D.

    Disease Control and Prevention Center / Director
    National Center for Global Health and Medicine Hospital

  • Dr. Nobuhiko OKABE, MD, Ph.D.

    Director General,
    Kawasaki City Institute for Public Health

  • Mr. Tatsuro KUZUKI

    Scientific Liaison
    DNDi Japan

  • Dr. Kazuhiro TATEDA, MD, PhD

    Department of Microbiology and Infectious Diseases/professor
    Toho University School of Medicine

  • Yasunori TAWARAGI, PhD

    Director, International Affairs
    Japan Pharmaceutical Manufacturers Association

  • Mr. Ryoji NORITAKE

    CEO and Board Member,
    Health and Global Policy Institute (HGPI)

  • Mr. Mitsushiro HIRAI

    Project Lead, Japan
    Bill & Melinda Gates Foundation

  • Shoji MIYAGAWA, DVM.MS

    Director, Division of Basic Medical Research,
    Department of Basic Medical Research,
    the Japan Agency for Medical Research and Development

B-2 Saraya Co., Ltd.

Infection prevention and control in the era with COVID-19: "New Normal" of healthcare-associated infections and public healthウィズコロナ時代の感染制御：医療関連感染対策と公衆衛生の“ニューノーマル”を考える

Moderator

Mr. Michikazu KOSHIBA

Head, Center on Global Health Architecture/
General Manager, Social Impact Partnership Business Dept.
MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.

Click here for a list of discussers

  • Ms. Shiho UMEZAWA, MS, RN

    Global Operations Division
    Saraya Co., Ltd.

  • Hiroki SAITO, MD, MPH

    Associate Professor, Department of Emergency and Critical Care Medicine
    St. Marianna University School of Medicine

  • Mr. Yu HARADA

    General Manager
    SARAYA Microbial Research Center, Biochemical Laboratory
    SARAYA Co. Ltd.

  • Prof. Didier PITTET

    Director, Infection Control Programme,
    University Hospital of Geneva,
    Geneva, Switzerland

C-2 FUJIFILM Toyama Chemical Co., Ltd.

Treatment Drug for COVID-19- Effectiveness and validationCOVID-19治療薬開発の現在と今後の展開について

Moderator

Prof. Nahoko SHINDO, MD, PhD

Senior Advisor,
WHO Health Emergencies Programme (WHE)，World Health Organization

Click here for a list of discussers

  • Prof. Satoshi IWATA, MD, PhD

    Director, Department of Infectious Diseases
    National Cancer Center Hospital

  • Prof. Yoshihiro KAWAOKA DVM, PhD

    Professor,
    Institute of Medical Science University of Tokyo

  • Dr. Junko SATO, PhD

    Office Director, Office of International Program,
    Pharmaceuticals and Medical Devices Agency

  • Dr. Yohei DOI, MD, PhD

    Departments of Microbiology and Infectious Diseases
    Fujita Health University
    Division of Infectious Diseases
    University of Pittsburgh

  • Dr. Richard H. KASZYNSKI

    Senior Medical Advisor
    Democratic Republic of Congo
15:40-15:55

Special Speech - Audrey Tang, Digital Minister, Taiwan特別講演　オードリー・タン氏（台湾・デジタル担当政務委員）

Audrey TANG

Taiwan’s Digital Minister
Executive Yuan

Click here for a list of discussers

  • Ms. Yuriko HOKAZONO

    Staff Writer
    Nikkei xTECH/Nikkei Computer
    Nikkei Business Publications, Inc.
15:55-17:00

Agenda3- Confronting COVID-19 (1): Medical and Social Innovation議題3　COVID-19に立ち向かうために何をすべきか①技術と社会のイノベーション

Moderator

Mr. Michikazu KOSHIBA

Head, Center on Global Health Architecture/
General Manager, Social Impact Partnership Business Dept.
MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Click here for a list of discussers

  • Dr. Shunichiro ITO, MD

    CEO / Representative Director
    LEBER Inc.

  • Mr. Kiyotaka EGUCHI

    Executive Officer, Public Policy and CSR
    LINE Corporation

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Mr. Kenichi KANEKO

    CEO
    LOKI CONSULTING Co.,Ltd.

  • Prof. Teppei SAKANO

    Group CEO & Founder
    Allm Inc.

  • Mr. Kazuya SAGINAWA

    CEO
    DataGateway Inc.

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE)，World Health Organization

  • Mr. Mitsuru TANIGUCHI

    LS Business Gene Testing Business Senior Vice President
    Sysmex Corporation

  • Mr. Susumu TSUBAKI

    Representative Director/CEO
    Asia Africa Investment and Consulting Pte. Ltd.(AAIC)

  • Prof. Hiroshi NISHIURA, M.D., Ph.D.

    Professor
    Kyoto University

  • Kuniaki MIYAKE MD,MSc

    CMO
    DeNA

  • Prof. Hiroaki MIYATA

    Professor
    Keio University

  • Mr. Yasuhide YAMADA

    Former Director-General of Coordination Office of Measures on Emerging Infectious Diseases, Cabinet Secretariat, Government of Japan
    Executive Officer, SHIMIZU CORPORATION

  • Mr. Guido GEERTS

    CEO
    Delft Imaging Systems

  • Dr. Lucica DITIU

    Executive Director
    Stop TB Partnership

  • Dr. Amit N THAKKER

    Chairman
    Africa Health Business
17:10-18:00

Bill & Melinda Gates Foundation’s Special Session: Embodiment of “Sanpo-yoshi”- Global Health and the Japanese private sectorビル＆メリンダ・ゲイツ財団特別セッション　「三方良し」を体現するグローバルヘルスと日本企業

Moderator

Ms. Mihoko KASHIWAKURA

Head of Japan Relations
Bill and Melinda Gates Foundation

Click here for a list of discussers

  • Dr. Nobuhiro ENDO

    Chairman of the Board
    NEC Corporation

  • Mr. Michikazu KOSHIBA

    Head, Center on Global Health Architecture/
    General Manager, Social Impact Partnership Business Dept.
    MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.

  • Isao TESHIROGI, Ph.D

    President and CEO
    Shionogi & Co., Ltd.

  • Dr. Mark SUZMAN

    Chief Executive Officer
    Bill & Melinda Gates Foundation

  • Dr. Christophe WEBER

    Representative Director, President & Chief Executive Officer
    Takeda Pharmaceutical Company Limited

DAY2November 7(SAT.) 11⽉7⽇（⼟）

* Please note that program details may be subject to change.
* Simultaneous interpretation is available at this conference

*プログラム内容は変更になる場合がございます。
*この会議では同時通訳が利用できます。

8:00-8:30

Keynote Session- Dr. Yasuhiro Suzuki, Former Vice-Minister for Health／Chief Medical & Global Health Officer, MHLW, Japan基調セッション　鈴木康裕・厚生労働省前医務技監に聞く

Moderator

Mr. Hisahiko YANO

Senior Staff Writer Editional Bureau
Nikkei Inc.

Click here for a list of discussers

  • Dr. Kiyoshi KUROKAWA

    Chair, Hideyo Noguchi Africa Prize Committee
    Chair of the Board, Health and Global Policy Institute
    Professor Emeritus, National Graduate Institute for Policy Studies and the University of Tokyo

  • Dr. SUZUKI Yasuhiro

    Advisor to the Minister
    Ministry of Health, Labor & Welfare

  • Mr. Omar QANDEEL

    Chairman
    Nippon Trading EST
8:30-10:00

Agenda4- Performance of PPP from the Conference and Future Issues議題4　これまでの感染症会議発PPPの実績と今後の課題

Moderator

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Click here for a list of discussers

  • Tatsuo IIYAMA, M.D.

    Director, Department of International Trials, Center for Clinical Sciences,
    National Center for Global Health and Medicine (NCGM)

  • Hajime INOUE, MD, MPH, DrPH　

    Deputy Director General
    Office for Novel Coronavirus Disease Control, Cabinet Secretariat

  • Ms. Catherine K. OHURA

    CEO & Executive Director
    GHIT Fund

  • Prof. Kazumasa OGURO

    Professor,
    Hosei University

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Prof. Akira KANEKO, MD, PhD, DTM&H

    Professor, Department of Parasitology,
    Osaka City University Graduate School of Medicine

  • Dr. Shigeyuki KANO, MD, PhD, Hon PhD(Mahidol)

    Director, Department of Tropical Medicine and Malaria,
    Research Institute, National Center for Global Health and Medicine (NCGM)

  • Prof. Kiyoshi KITA

    Dean and Professor, School of Tropical Medicine and Global Health, Nagasaki University

  • Prof. Osamu KUNII, MD, MPH, PhD,　

    Head, Strategy, Investment and Impact Division (SIID)
    The Global Fund to Fight AIDS, Tuberculosis and Malaria

  • Ms. Takuko SAWADA

    Director of the Board, Executive Vice President
    Head, Integrated Disease Care Division
    Shionogi & Co., Ltd.

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE)，World Health Organization

  • Prof. Dr. Tomohiko SUGISHITA

    Department of International Affairs and Tropical Medicine
    Tokyo Women’s Medical University

  • Manabu SUMI, MD, MPH, PhD

    Director, Health Service Division
    Ministry of Health, Labour and Welfare

  • Kengo SONODA, PhD

    Development Department / General Manager
    KM Biologics Co., Ltd.

  • Dr. Kazuhiro TATEDA, MD, PhD

    Department of Microbiology and Infectious Diseases/professor
    Toho University School of Medicine

  • Yasunori TAWARAGI, PhD

    Director, International Affairs
    Japan Pharmaceutical Manufacturers Association

  • Dr. Hiroyuki NODA, MD, PhD

    Office for Novel Coronavirus Disease Control,
    Office for Pandemic Influenza and New Infectious Diseases
    & Coordination Office of Measures on Emerging Infectious Disease / Councilor
    Cabinet Secretariat

  • Mr. Yoshihide HIRUTA

    Director of International Cooperation, International Business Management, Global Support
    Sysmex Corporation

  • Shoji MIYAGAWA, DVM.MS

    Director, Division of Basic Medical Research,
    Department of Basic Medical Research,
    the Japan Agency for Medical Research and Development

  • Dr. Yasuyoshi MORI, PhD

    General Manager
    Biochemical Research Laboratory II
    Eiken Chemical Co.,Ltd.

  • Takeo MOROOKA, MD, MPH

    Executive Officer, Head of Health Policy and Corporate Support
    MSD K.K.

  • Dr. Yasuhiro YASUTOMI, DVM, PhD

    Director, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN)
    Professor, Division of Immunoregulation, Department of Molecular and Experimental Medecine, Mie University Graduate School of Medicine

  • Mr. Yasuhide YAMADA

    Former Director-General of Coordination Office of Measures on Emerging Infectious Diseases, Cabinet Secretariat, Government of Japan
    Executive Officer, SHIMIZU CORPORATION

  • Prof. Dr. Suchinda MALAIVIJITNOND, Ph.D.

    Professor at Chulalongkorn University, and Director of the National Primate Research Center of Thailand
    Chulalongkorn University (NPRCT-CU)

  • Dr. Jean-Pierre PACCAUD, PhD

    Director of Business Development and Corporate Strategy
    Global Antibiotic R&D Partnership Foundation (GARDP)
10:05-10:25

Special Session I : Challenges in Preventing and Controlling Emerging Infectious Diseases - A look at BIKEN's Vaccine Development Platform特別セッション 新興感染症予防・制御に向けた課題～BIKENのワクチン開発プラットフォームに見る

Moderator

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Click here for a list of discussers

  • Mr. Shiro TAKEKAWA

    Division Manager / Basic Research Department Innovative Vaccine Research And Development Division
    The Research Foundation for Microbial Diseases of Osaka University

  • Koichi YAMANISHI, M.D., Ph.D.

    Director General
    The Research Foundation for Microbial Diseases of Osaka University
10:30-10:50

Special Session II: Expectations for development of COVID-19 vaccines in Japan: Development of an inactivated vaccine by KM Biologics特別セッション 国産ワクチンへの期待：KMバイオロジクスによるCOVID-19不活化ワクチンの開発

Moderator

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Click here for a list of discussers

  • Kengo SONODA, PhD

    Development Department / General Manager
    KM Biologics Co., Ltd.

  • Mr. Toshiaki NAGASATO

    President and Representative Director
    KM Biologics Co.,Ltd
10:50-12:00

Agenda5- Confronting COVID-19 (2): Pharmaceutical and Medical Devices議題5　COVID-19に立ち向かうために何をすべきか②ワクチン、治療薬、検査薬、消毒薬

Moderator

Mr. Junichi TAKI

Editorial Bureau, Senior Staff Writer
Nikkei Inc.

Dr. Yasuhiro YASUTOMI, DVM, PhD

Director, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN)
Professor, Division of Immunoregulation, Department of Molecular and Experimental Medecine, Mie University Graduate School of Medicine

Click here for a list of discussers

  • Dr. Kazunari ASANUMA, MD, PhD

    Councillor for Environmental Health and Food Safety, Minister's Secretariat,
    Ministry of Health, Labour and Welfare

  • Takashi ISHIZAKI, Ph.D.

    APAC BIOVIA Industry Process Consultant Senior
    Dassault Systemes KK

  • Mr. Masayuki IMAGAWA, M.B.A., M.Sc., R.Ph.

    Head, Japan Vaccine Business Unit,
    Takeda Pharmaceutical Co., Ltd
    Chief Executive,
    Japan Association of Vaccine Industries

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Mr. Yusuke SARAYA

    President
    Saraya Co., Ltd.

  • Ms. Takuko SAWADA

    Director of the Board, Executive Vice President
    Head, Integrated Disease Care Division
    Shionogi & Co., Ltd.

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE)，World Health Organization

  • Kengo SONODA, PhD

    Development Department / General Manager
    KM Biologics Co., Ltd.

  • Mr. Shiro TAKEKAWA

    Division Manager / Basic Research Department Innovative Vaccine Research And Development Division
    The Research Foundation for Microbial Diseases of Osaka University

  • Mr. Hisato DOI

    President, Representative Director
    Evec, Inc.

  • Kenta NODA, PhD

    Vice President
    Applied Diagnostic Research Group, Central Research Laboratories
    Sysmex Corporation

  • Hideyuki FUKUDA, Ph.D.

    Director
    In vitro Diagnostics Business
    Kyorin Pharmaceutical Co., Ltd.

  • Yasuhiro FUJIWARA, MD, PhD

    Chief Executive
    Pharmaceuticals and Medical Devices Agency

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

  • Ryuichi MORISHITA, MD, PhD

    Professor of Department of Clinical Gene Therapy, Center of Medical
    Innovation and Translational Research School of Medicine, Osaka University

  • Prof. Jiro YASUDA PhD, DVM

    Director, National Research Center for the Control and Prevention of Infectious Diseases (CCPID) &
    Professor, Institute of Tropical Medicine (NEKKEN), Nagasaki University

  • Masayuki YABUTA, Ph.D.

    Executive Officer Head of Biologics Division
    Daiichi Sankyo Co., Ltd.

  • Mr. Hiroshi YOSHIDA

    Director, R&D,
    NIPRO CORPORATION

  • Mr. Hajime WATARI

    Director and Vice President, GM of Global Business
    EIKEN Chemical Co.,Ltd.

  • Professor Sir John BELL

    Regius Professor of Medicine
    University of Oxford

  • Dr. Seth BERKLEY

    CEO
    Gavi, the Vaccine Alliance
12:05-13:05

Lunch Session - The Japan Pharmaceutical Manufacturers Association (JPMA):Strengthening Future Measures against Communicable Diseases through PPP -Towards Prompt Supply of Essential Therapeutic Drugs and Vaccines-ランチセッション（日本製薬工業協会）産学官連携による今後の感染症対策の強化　～必要な治療薬・ワクチンの迅速供給のために～

Moderator

Mr. Ryousuke HARADA

Senior Exective Editor
Nikkei Inc.

Click here for a list of discussers

  • Ms. Mihoko KASHIWAKURA

    Head of Japan Relations
    Bill and Melinda Gates Foundation

  • Dr. Tokuaki SHOBAYASHI, MD, Msc. , PhD

    Director General
    Ministry of Health, Labor & Welfare

  • Dr. Kazuhiro TATEDA, MD, PhD

    Department of Microbiology and Infectious Diseases/professor
    Toho University School of Medicine

  • Mr. George NAKAYAMA

    Chairman
    Japan Pharmaceutical Manufacturers Association
13:10-14:00 Breakout Session A-3 分科会　A-3

A-3 SYSMEX CORPORATION

Be confident fighting malaria – Innovative diagnostics towards achieving SDGsマラリア検査のイノベーションとSDGsへの貢献

Moderator

Prof. Dr. Tomohiko SUGISHITA

Department of International Affairs and Tropical Medicine
Tokyo Women’s Medical University

Click here for a list of discussers

  • Mr. Ken SHIBUSAWA

    Chief Executive Officer
    Shibusawa and Company, Inc

  • Dr. Amit N THAKKER

    Chairman
    Africa Health Business
14:05-14:50

Special Session III: Speeches from Governors特別セッション　知事に聞く各自治体の取り組み

Moderator

Prof. Dr. KANO Mitsunobu, MD/PhD

Vice Executive Director and Professor
Okayama University
Science and Technology Co-Advisor to Minister for Foreign Affairs of Japan

Mr. Ryoji NORITAKE

CEO and Board Member,
Health and Global Policy Institute (HGPI)

Click here for a list of discussers

  • Ms. KOIKE Yuriko

    Governor of Tokyo.

  • Mr. Naomichi SUZUKI

    Hokkaido Government/Governor

  • Mr. YOSHIMURA Ｈirofumi

    Governor of Osaka
14:55-16:20

Agenda6- Coexisting with COVID-19 ～The Role of Japanese Initiatives議題6　COVID-19との共生における日本発イニシアチブのあるべき姿～国際協力、国際機関の役割とは

Moderator

Prof. Dr. KANO Mitsunobu, MD/PhD

Vice Executive Director and Professor
Okayama University
Science and Technology Co-Advisor to Minister for Foreign Affairs of Japan

Mr. Ryoji NORITAKE

CEO and Board Member,
Health and Global Policy Institute (HGPI)

Click here for a list of discussers

  • Dr. Kazunari ASANUMA, MD, PhD

    Councillor for Environmental Health and Food Safety, Minister's Secretariat,
    Ministry of Health, Labour and Welfare

  • Hajime INOUE, MD, MPH, DrPH　

    Deputy Director General
    Office for Novel Coronavirus Disease Control, Cabinet Secretariat

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Prof. Osamu KUNII, MD, MPH, PhD,　

    Head, Strategy, Investment and Impact Division (SIID)
    The Global Fund to Fight AIDS, Tuberculosis and Malaria

  • Dr. Kiyoshi KUROKAWA

    Chair, Hideyo Noguchi Africa Prize Committee
    Chair of the Board, Health and Global Policy Institute
    Professor Emeritus, National Graduate Institute for Policy Studies and the University of Tokyo

  • Dr. Tatsuya KONDO

    Chief Executive Officer
    Medical Excellence JAPAN　

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE)，World Health Organization

  • Manabu SUMI, MD, MPH, PhD

    Director, Health Service Division
    Ministry of Health, Labour and Welfare

  • Dr. Takao TODA Ph.D.

    Special Advisor to the President（Human Security and Global Health）
    Japan International Cooperation Agency

  • Mr. George NAKAYAMA

    Chairman
    Japan Pharmaceutical Manufacturers Association

  • Dr. Seth BERKLEY

    CEO
    Gavi, the Vaccine Alliance

  • Mr. Thomas B. CUENI

    Director General
    International Federation of Pharmaceutical Manufacturers & Associations

  • Dr. Richard HATCHETT

    CEO
    CEPI - Coalition for Epidemic Preparedness Innovations

  • Mr. Peter SANDS

    Executive Director
    The Global Fund to Fight AIDS, Tuberculosis and Malaria

  • Ms. Martina SZABO

    Lead, COVID Action Platform
    WORLD ECONOMIC FORUM

  • Dr. Amit N THAKKER

    Chairman
    Africa Health Business
16:30-17:30

Summary Sessionサマリーセッション

Moderator

Dr. Shigeru OMI, MD, PhD

President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
World Health Organization (WHO), Regional Office for Western Pacific

Click here for a list of discussers

  • Hajime INOUE, MD, MPH, DrPH　

    Deputy Director General
    Office for Novel Coronavirus Disease Control, Cabinet Secretariat

  • Ms. Mihoko KASHIWAKURA

    Head of Japan Relations
    Bill and Melinda Gates Foundation

  • Prof. Dr. KANO Mitsunobu, MD/PhD

    Vice Executive Director and Professor
    Okayama University
    Science and Technology Co-Advisor to Minister for Foreign Affairs of Japan

  • Prof. Kiyoshi KITA

    Dean and Professor, School of Tropical Medicine and Global Health, Nagasaki University

  • Mr. Michikazu KOSHIBA

    Head, Center on Global Health Architecture/
    General Manager, Social Impact Partnership Business Dept.
    MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE)，World Health Organization

  • Prof. Dr. Tomohiko SUGISHITA

    Department of International Affairs and Tropical Medicine
    Tokyo Women’s Medical University

  • Mr. Junichi TAKI

    Editorial Bureau, Senior Staff Writer
    Nikkei Inc.

  • Dr. Kazuhiro TATEDA, MD, PhD

    Department of Microbiology and Infectious Diseases/professor
    Toho University School of Medicine

  • Mr. Ryoji NORITAKE

    CEO and Board Member,
    Health and Global Policy Institute (HGPI)

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Kazuki HOSHINO, PhD

    Director
    Vaccine Business Department
    Daiichi Sankyo Co., Ltd.

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

  • Dr. Yasuhiro YASUTOMI, DVM, PhD

    Director, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN)
    Professor, Division of Immunoregulation, Department of Molecular and Experimental Medecine, Mie University Graduate School of Medicine

  • Mr. Yasuhide YAMADA

    Former Director-General of Coordination Office of Measures on Emerging Infectious Diseases, Cabinet Secretariat, Government of Japan
    Executive Officer, SHIMIZU CORPORATION

  • Dr. Yoshinori YAMANO, Ph.D.

    Chief Scientific Officer for Infectious Diseases,
    Pharmaceutical Research Division,
    SHIONOGI & CO., LTD.
17:30-18:00

Conclusion/Statementステートメント策定

Moderator

Dr. Shigeru OMI, MD, PhD

President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
World Health Organization (WHO), Regional Office for Western Pacific

Click here for a list of discussers

  • Hajime INOUE, MD, MPH, DrPH　

    Deputy Director General
    Office for Novel Coronavirus Disease Control, Cabinet Secretariat

  • Ms. Mihoko KASHIWAKURA

    Head of Japan Relations
    Bill and Melinda Gates Foundation

  • Prof. Dr. KANO Mitsunobu, MD/PhD

    Vice Executive Director and Professor
    Okayama University
    Science and Technology Co-Advisor to Minister for Foreign Affairs of Japan

  • Prof. Kiyoshi KITA

    Dean and Professor, School of Tropical Medicine and Global Health, Nagasaki University

  • Mr. Michikazu KOSHIBA

    Head, Center on Global Health Architecture/
    General Manager, Social Impact Partnership Business Dept.
    MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE)，World Health Organization

  • Prof. Dr. Tomohiko SUGISHITA

    Department of International Affairs and Tropical Medicine
    Tokyo Women’s Medical University

  • Mr. Junichi TAKI

    Editorial Bureau, Senior Staff Writer
    Nikkei Inc.

  • Dr. Kazuhiro TATEDA, MD, PhD

    Department of Microbiology and Infectious Diseases/professor
    Toho University School of Medicine

  • Mr. Ryoji NORITAKE

    CEO and Board Member,
    Health and Global Policy Institute (HGPI)

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Kazuki HOSHINO, PhD

    Director
    Vaccine Business Department
    Daiichi Sankyo Co., Ltd.

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

  • Dr. Yasuhiro YASUTOMI, DVM, PhD

    Director, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN)
    Professor, Division of Immunoregulation, Department of Molecular and Experimental Medecine, Mie University Graduate School of Medicine

  • Mr. Yasuhide YAMADA

    Former Director-General of Coordination Office of Measures on Emerging Infectious Diseases, Cabinet Secretariat, Government of Japan
    Executive Officer, SHIMIZU CORPORATION

  • Dr. Yoshinori YAMANO, Ph.D.

    Chief Scientific Officer for Infectious Diseases,
    Pharmaceutical Research Division,
    SHIONOGI & CO., LTD.
18:00-18:10

General Overview総評

Prof. Keizo TAKEMI

Member of the House of Councillors,
Vice-Chairperson, General Assembly of Party Members of the House of Councillors
Chairperson, Special Committee on Global Health Strategy of LDP
Acting-Chairperson, Headquarters for Novel Coronavirus of LDP
Chairperson, Subcommittee on Governance for Infectious Diseases of LDP
WHO Goodwill Ambassador for Universal Health Coverage
Senior Fellow, Japan Center for International Exchange (JCIE)
Visiting Professor at Nagasaki University

topへ戻る